Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James P Allison

Showing results (201-210 of 206) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 206 results.
Nature Medicine|March 17, 2023
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trialTina Cascone, Cheuk H Leung, Annikka Weissferdt, et al.
Journal of Translational Medicine|October 5, 2012
Cancer classification using the Immunoscore: a worldwide task forceJérôme Galon, Franck Pagès, Francesco M Marincola, et al.
Nature|August 20, 2025
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapyErez N Baruch, Frederico O Gleber-Netto, Priyadharsini Nagarajan, et al.
Nature Medicine|July 9, 2021
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockadeMiles C Andrews, Connie P M Duong, Vancheswaran Gopalakrishnan, et al.
Science (New York, N.Y.)|December 23, 2021
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy responseChristine N Spencer, Jennifer L McQuade, Vancheswaran Gopalakrishnan, et al.
Journal of Translational Medicine|December 16, 2011
Defining the critical hurdles in cancer immunotherapyBernard A Fox, Dolores J Schendel, Lisa H Butterfield, et al.
Pageof 21

Showing results (201-210 of 206) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 206 results.
Nature Medicine|March 17, 2023
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trialTina Cascone, Cheuk H Leung, Annikka Weissferdt, et al.
Journal of Translational Medicine|October 5, 2012
Cancer classification using the Immunoscore: a worldwide task forceJérôme Galon, Franck Pagès, Francesco M Marincola, et al.
Nature|August 20, 2025
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapyErez N Baruch, Frederico O Gleber-Netto, Priyadharsini Nagarajan, et al.
Nature Medicine|July 9, 2021
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockadeMiles C Andrews, Connie P M Duong, Vancheswaran Gopalakrishnan, et al.
Science (New York, N.Y.)|December 23, 2021
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy responseChristine N Spencer, Jennifer L McQuade, Vancheswaran Gopalakrishnan, et al.
Journal of Translational Medicine|December 16, 2011
Defining the critical hurdles in cancer immunotherapyBernard A Fox, Dolores J Schendel, Lisa H Butterfield, et al.
Pageof 21